Heron Therapeutics (HRTX) Tops Q4 EPS by 5c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts HRTX Hot Sheet
Join SI Premium – FREE
Heron Therapeutics (NASDAQ: HRTX) reported Q4 EPS of $0.02, $0.05 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $40.78 million versus the consensus estimate of $37.3 million.
GUIDANCE:
Heron Therapeutics sees Q1 2025 revenue of $153-163 million, versus the consensus of $160.6 million.
For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- enVVeno Medical (NVNO) Misses Q3 EPS by 302c
- Stifel on FedEx Freight (FDXF): 'Enters Its Post-Breakup Era - Time to Hit the Gym and Focus on Itself'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
